Curetis

Multiplex PCR Panels for Joint Infections on the Horizon

OpGen Posts 54 Percent Increase in Preliminary Q3 Revenues, Consolidates Product Portfolio

Curetis Receives €350K German Government Grant to Develop Carbapenem Resistance Test

OpGen Nabs CE-IVD Mark for SARS-CoV-2 Kit

OpGen Q2 Revenues Climb 20 Percent

Curetis Gains Access to Additional €5 Million Debt Financing for COVID-19 R&D

OpGen Q1 Revenues Drop 38 Percent

Curetis, Karolinska Institute Collaborate to Identify Bacterial Co-Infections in COVID-19 Patients

OpGen Q1 Preliminary Revenues Down 38 Percent

OpGen Fourth Quarter Revenues Increase 8 Percent

Curetis Preliminary 2019 Revenues Up 64 Percent

OpGen Preliminary 2019 Revenues up 19 Percent

Curetis Signs Vietnam Distribution Deal for Unyvero Dx System, Cartridges

Ares Genetics Collaborates With BGI on Coronavirus Testing in Europe

Luminex, Microgenics, Sentinel Diagnostics, Others Get FDA Clearances in December

FDA Clears Curetis Lower Respiratory Tract Infections Panel

Curetis Reports 17 Percent Revenue Increase for First Nine Months of 2019

Curetis Posts 17 Percent Increase in Preliminary Revenues for First Nine Months of 2019

OpGen Posts 17 Percent Increase in Q3 Revenues

In Brief This Week: OpGen, Owlstone Medical, Oncimmune, and More